Tesamorelin vs MK-677: Glucose-Neutral Phase 3 Evidence vs Cheap Oral Glucose Cost

Tesamorelin and MK-677 are both used to elevate GH and IGF-1 in bodybuilding and TRT contexts, but they work through fundamentally different mechanisms with fundamentally different metabolic consequences.

Tesamorelin is a synthetic GHRH(1-44) analog with a trans-3-hexenoic acid cap that blocks DPP-IV cleavage. It binds the pituitary GHRH receptor and triggers endogenous pulsatile GH release. The negative feedback loop (IGF-1 to somatostatin) remains intact, so GH exposure is physiological. FDA-approved 2010 for HIV-associated lipodystrophy. Phase 3 evidence in 806 patients over 52 weeks (Falutz 2010, PMID 20554713).

MK-677 (ibutamoren) is an oral non-peptide ghrelin receptor agonist. It mimics ghrelin to drive continuous GH release, which raises IGF-1 substantially but at the cost of insulin resistance because the GH signal is not pulsatile. Not FDA-approved for any indication. Best human evidence comes from Chapman 1996 (PMID 8954023, elderly subjects) and Nass 2008 (PMID 18981485, 2-year RCT in healthy older adults).

The mechanistic difference is the source of every clinical difference. Pulsatile GHRH stimulation preserves the inter-pulse insulin sensitivity that continuous ghrelin agonism erodes. This is why tesamorelin keeps fasting glucose stable over 52 weeks while MK-677 raises it 25-27% in 4 weeks.

Mechanism:

• Tesamorelin: GHRH receptor agonist, pulsatile GH release, intact negative feedback
• MK-677: Ghrelin receptor agonist, continuous GH stimulation, blunted feedback

Route and convenience:

• Tesamorelin: subcutaneous injection, once daily
• MK-677: oral capsule, once daily (the convenience advantage)

Evidence base:

• Tesamorelin: FDA-approved 2010; Phase 3 RCT in 806 patients over 52 weeks (Falutz 2010); confirmed in healthy men clamp study (Stanley 2011)
• MK-677: Not FDA-approved; best evidence is Nass 2008 2-year RCT (n=65 healthy older adults)

IGF-1 elevation:

• Tesamorelin: +81% (Falutz 2007 NEJM, PMID 18057338); +108 ng/mL absolute (Falutz 2010 pooled)
• MK-677: +88% at 4 weeks (Chapman 1996, 141 to 265 mcg/L)

Visceral fat data:

• Tesamorelin: -15.2% to -15.4% (Falutz 2007; Stanley 2014 JAMA, PMID 25038357)
• MK-677: No direct VAT outcome trial; +1.1 kg fat-free mass at 2 years (Nass 2008) but VAT not measured

Fasting glucose (the critical difference):

• Tesamorelin: neutral over 52 weeks in 806 patients (responders +1 mg/dL at week 26)
• MK-677: +26% at 4 weeks (5.4 to 6.8 mmol/L, Chapman 1996); fasting glucose elevation and insulin resistance documented at 12 months in Nass 2008

HbA1c:

• Tesamorelin: +0.1% in responders, +0.3% in non-responders at week 26
• MK-677: mildly elevated at 12 months in Nass 2008; 37% of subjects trending toward pre-diabetic range

Insulin sensitivity (clamp data):

• Tesamorelin: insulin-stimulated glucose uptake unchanged (p=0.61) in healthy men (Stanley 2011)
• MK-677: insulin sensitivity decreased at 12 months in healthy older adults (Nass 2008)

Triglycerides:

• Tesamorelin: -50 mg/dL at 26 weeks (Falutz 2007); -68 mg/dL at 52 weeks in responders
• MK-677: variable; no specific triglyceride-lowering claim in published trials

Cost (grey market peptide pricing):

• Tesamorelin (Egrifta brand): USD $2,000+/month; grey market USD $300-500/month
• MK-677: USD $40-70/month

FDA status and safety surveillance:

• Tesamorelin: FDA-approved, post-marketing surveillance, clear prescribing information
• MK-677: Unregulated, no post-marketing surveillance, grey market quality varies

Choose tesamorelin if:

• You have metabolic syndrome, central adiposity, or visceral fat as a specific target
• You are on TRT and want to preserve insulin sensitivity
• You can afford the cost (USD $300-500/month grey market)
• You have time for daily subcutaneous injections
• You want evidence-based clinical confidence (Phase 3 RCT data, FDA approval)
• You have NAFLD or fatty liver from oral AAS history (Stanley 2019 Lancet HIV data)

Choose MK-677 if:

• Cost is the dominant constraint
• You strongly prefer oral over injectable
• Your baseline insulin sensitivity is excellent (HOMA-IR <1.5) and you can tolerate some glucose drift
• You are not on cycle with compounds that already worsen insulin sensitivity (19-nors, EQ, tren)
• You are willing to monitor fasting glucose and HbA1c every 4 weeks and discontinue if drift occurs

Do not stack them: Layering pulsatile GHRH stimulation on top of continuous ghrelin agonism produces additive GH/IGF-1 exposure but removes tesamorelin's pulsatile metabolic advantage. Pick one axis.

For TRT users with metabolic syndrome: Tesamorelin is the right tool. The Mangili 2015 sub-analysis (PMID 26457580) shows the metabolic syndrome subgroup responds biggest to tesamorelin (-24.4 cm² VAT vs +8.6 cm² placebo), while MK-677 would push fasting glucose deeper into pre-diabetic range in the same patients.

For lean, insulin-sensitive bodybuilders looking for cheap IGF-1: MK-677 is a reasonable choice if you can tolerate the glucose drift and your baseline HOMA-IR is excellent. Run with quarterly bloodwork and discontinue if HbA1c crosses 5.7%.